Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00724
|
|||||
| Drug Name |
Dofetilide
|
|||||
| Synonyms |
1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE; Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; Dofetilida; Dofetilida [INN-Spanish]; Dofetilide (JAN/USAN/INN); Dofetilide [USAN:BAN:INN]; Dofetilidum; Dofetilidum [INN-Latin];Tikosyn (TN); Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; Tikosyn; Tikosyn, UK68798, Dofetilide; UK 68,798; UK 68798; UK-68,798; UK-68798; Xelide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Maintenance of normal sinus rhythm [ICD11: BC81.3] | Approved | [1] | |||
| Therapeutic Class |
Antiarrhythmic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H27N3O5S2
|
|||||
| Canonical SMILES |
CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
|
|||||
| InChI |
InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
|
|||||
| InChIKey |
IXTMWRCNAAVVAI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 115256-11-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 441.6 | Topological Polar Surface Area | 122 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 11 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
1.8
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:4681
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MATE1 | Transporter Info | Multidrug and toxin extrusion protein 1 | Substrate | [2] | |
| MATE2 | Transporter Info | Multidrug and toxin extrusion protein 2 | Substrate | [2] | ||
| OCT-2 | Transporter Info | Organic cation transporter 2 | Substrate | [2] | ||
| References | ||||||
| 1 | Dofetilide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | FDA Drug Development and Drug Interactions | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.